• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Optimal Antidepressant Doses in Major Depression

Optimal Antidepressant Doses in Major Depression

March 9, 2020
Kristen Gardner, PharmD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Kristen Gardner, PharmD. Dr. Gardner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Furukawa TA et al, Lancet Psychiatry;2019;6(7):601–609


Type of study: Systematic review and meta-analysis


Most antidepressants do not have a linear response curve. In other words, the benefits level off as the dose goes up. If the dose gets too high, the side effects start to outweigh those diminishing returns. What’s not clear is where the “sweet spot” lies for each antidepressant, and this study set out to capture that optimal dose range.


This dose-response meta-analysis included 77 double-blind, randomized, placebo-controlled trials of fixed-dose SSRIs (except fluvoxamine), venlafaxine, and mirtazapine in major depression (n = 19,365). Median trial length was 8 weeks (range = 4–12 weeks). Primary outcomes were efficacy (treatment response defined as 50% or greater reduction in depressive symptoms), tolerability (dropouts due to adverse effects), and acceptability (dropouts for any reason).


The best balance of efficacy, tolerability, and acceptability was achieved at low to medium doses of these antidepressants (see table). At higher doses (> 40 mg of fluoxetine equivalents), the benefits plateaued and dropouts from side effects showed steep, linear-to-­exponential curves. Venlafaxine was unique in that its efficacy continued to increase up to 375 mg, though it started slowing at doses above 150 mg.



Table: Antidepressant Dosages


Table: Table: Antidepressant Dosages


(Click to view full-size PDF.)



 



Graph: Relationship of Dose to Response and Adverse Effects for SSRIs Across 99 Treatment Groups


Graph: Relationship of Dose to Response and Adverse Effects for SSRIs Across 99 Treatment Groups


(Click to view full-size PDF.)



TCPR’s TAKE
When a patient does not recover fully on an antidepressant, it’s tempting to keep raising the dose. That strategy may work sometimes, but this study suggests that for many on second-generation antidepressants, an increased dose is more likely to cause side effects than therapeutic gains. If you go to a higher dose, measure the outcomes, and consider dropping back down if there’s no clear improvement.


General Psychiatry
KEYWORDS antidepressants bupropion citalopram depression depressive_disorder escitalopram fluoxetine mirtazapine paroxetine pharmacology pharmacology-tips research research-update sertraline ssris venlafaxine wellbutrin
Kristen Gardner, PharmD.

Olanzapine for Anorexia Nervosa

More from this author
www.thecarlatreport.com
Issue Date: March 9, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Bipolar II, TCPR, March 2020
Oxcarbazepine: Close, but no Cigar
Psychopharmacology in Bipolar II
Lumateperone and lemborexant
Optimal Antidepressant Doses in Major Depression
Highlight From This Issue
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.